Momenta Continues Its Transition

Momenta Pharmaceuticals (NASDAQ: MNTA) continues its transition from a drugmaker specializing in hard-to-make generic drugs to one focused on novel products. The financial numbers aren't going to be pretty during the transition, so investors should focus on the pipeline.

Fortunately, with $380 million in the bank, Momenta has a solid runway to get to at least proof of concept for its novel products.

Metric

Continue reading

Quelle Fool.com